The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014
Title, commencement and application1.
(1)
The title of these Regulations is the National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 and they come into force on 14 February 2014.
(2)
These Regulations apply in relation to Wales.
Amendment of the National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 20042.
(1)
(2)
In Schedule 2 (drugs on medicines to be ordered only in certain circumstances)—
(a)
in the heading to the Schedule, for “on” substitute “or”;
(b)
in column 1 of the table (drugs), for the treatment of erectile dysfunction, omit—
(i)
“(Caverject), (MUSE), (Viridal)”,
(ii)
“(Uprima)”,
(iii)
“(Erecnos)” (in both places where it appears),
(iv)
“(Viagra)”,
(v)
“(Cialis)”, and
(vi)
“(Levitra)”;
(c)
in column 2 of the table (patient)—
(i)
at the beginning of the entry relating to drugs for the treatment of erectile dysfunction, insert “(1) The following patients with erectile dysfunction—”, and
(ii)
“;
(2)
Any patient”; and
(d)
in column 3 (condition), opposite “(2) Any patient” in column 2, insert the words “Treatment of a condition other than erectile dysfunction, in respect of which the drug ordered is in receipt of a UK or EU marketing authorisation for the treatment of that condition”.
These Regulations amend the National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004 (“the principal Regulations”) which make provision as to the drugs, medicines or other substances that may be ordered for patients in the provision of medical services under a general medical services contract within the meaning of section 42 of the National Health Service (Wales) Act 2006.
Regulation 2 makes amendments to the table in Schedule 2 to the principal Regulations (drugs or medicines to be ordered only in certain circumstances) which restricts the circumstances in which certain drugs and medicines specified in column 1 of the table may be ordered for the category of patients described in column 2 of the table for the purpose specified in column 3 of the table. A typographical error in the heading to this Schedule is corrected and the entry in the table relating to certain specified drugs which may be ordered for the treatment of erectile dysfunction has been amended so as to clarify that any such drug may also be ordered for any patient for the purpose of treating a medical condition, other than erectile dysfunction, in respect of which the drug ordered is in receipt of a UK or EU marketing authorisation for the treatment of that condition.
The Welsh Ministers’ Code of Practice on the carrying out of Regulatory Impact Assessments was considered in relation to these Regulations. As a result, it was not considered necessary to carry out a regulatory impact assessment as to the likely costs and benefits of complying with these Regulations.